Warsaw, Mazowieckie, Poland
Realization of the project: “Development of an experimental anti-cancer immunotherapy based on therapeutic mRNAs of modified innovative cap analogues of a new generation” (no. POIR.01.01.01-00-0920/19)
Realization of the projects: 1. Development of new therapies based on stimulation of antitumor immunity (STRATEGMED 2/265503/3/NCBIR/15) 2. Study of the role of cancer- and exosome-derived arginases in mitigating antitumor immune response in ovarian cancer (OPUS 2013/11/B/NZ6/02790) 3. Role of arginase-1 in modulation of antitumor activity of checkpoint inhibitors (OPUS 2016/23/B/NZ6/03463) 4. Arginase-1 as the potential target in treatment of multiple myeloma and modulator of cardiotoxicity effects of proteasome inhibitors (OPUS 2017/25/B/NZ6/01139) 5. Development strategy of research in the field of immune-oncology (granted by Ministry of Science and Higher Education within “Regional excellence initiative” programme) 6. Searching for novel strategies improving cancer immunotherapy (European Research Council Starting Grant)
Radcliffe Department of Medicine, Prof. Vincenzo Cerundolo Research Group Twinning visit at Wheatherall Institute of Molecular Medicine Aim of the visit: to study the role of arginine degrading enzymes in the tumor development (twinning visit within the STREAM project - Strategies Towards Excellence in Immuno-Oncology granted by European Union within research and innovation programme, Horizon 2020, grant #692180)
Behavior and Metabolism Research Laboratory Performing behavioral experiments on rats